Clinical trials
Amyloidosis clinical trials
Below are recruiting amyloidosis clinical trials, each written for real people, not researchers. We’re tracking 155 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07335887RecruitingPhase 2
Sonrotoclax and dexamethasone with or without daratumumab for AL amyloidosis with t(11;14)
This trial tests a new drug combination for people with a specific type of AL amyloidosis (light chain amyloidosis) that has a genetic marker called t(11;14). The treatment includes Sonrotoclax (a targeted therapy) plus steroids, and possibly another drug called daratumumab, to see if it can help control the disease.
BeijingAges 18 years+ - NCT05951816RecruitingPhase 1
Imaging study for amyloidosis in heart and body
This study tests a new imaging agent (99mTc-p5+14) that helps doctors see amyloid deposits in the body, especially in the heart. It is for healthy volunteers and people with AL or ATTR amyloidosis that has affected the heart.
Knoxville, TennesseeAges 18 years+ - NCT07250269RecruitingPhase 1
CAR-T therapy for AL amyloidosis
This trial tests a new CAR-T cell therapy (GC012F) that targets two proteins, CD19 and BCMA, on abnormal plasma cells. It's for people with AL amyloidosis who have already tried at least one treatment.
BeijingAges 18 years+ - NCT05139797Recruiting
AI-guided heart ultrasound screening for suspected amyloidosis
This study tests whether an artificial-intelligence system can help decide who should get a special heart workup for a rare disease called cardiac amyloidosis. If you have signs that make doctors suspect this, the AI-guided ultrasound screening may help find it sooner.
Los Angeles, CaliforniaAges 18 years+ - NCT06664866Enrolling by invitation
AI Screening for Heart Amyloidosis
This trial tests an AI program that looks at your heart ultrasound (echocardiogram) to find possible signs of cardiac amyloidosis early. It helps doctors decide if more testing is needed.
Los Angeles, CaliforniaAges 22 years+ - NCT06096675Recruiting
Physical activity study for cardiac amyloidosis patients
This study tests whether a 12-week supervised exercise program is safe and helpful for people with cardiac amyloidosis and heart failure. It aims to see if regular exercise can improve how you feel and function.
Charlotte, North CarolinaAges 18 years+ - NCT07224672RecruitingPhase 2
Study of a drug combo for newly diagnosed AL amyloidosis
This trial tests a combination of four drugs (belantamab mafodotin, cyclophosphamide, bortezomib, and dexamethasone) for people newly diagnosed with AL amyloidosis who cannot have a stem cell transplant. The goal is to see if this combination is safe and effective at stopping the abnormal proteins from damaging your organs.
Rochester, MinnesotaAges 18 years+ - NCT04535349Recruiting
Imaging heart uptake of bone tracer in ATTR amyloidosis
This study uses special imaging tracers to see how much they build up in the heart in people with cardiac transthyretin (ATTR) amyloidosis. It may help researchers better measure disease activity and understand who benefits from treatments like tafamidis.
CaenAges 18–100 - NCT04587648Recruiting
Treating cardiac amyloidosis in heart failure with preserved ejection
This trial studies people with heart failure with preserved ejection fraction (HFpEF) and cardiac amyloidosis (an abnormal protein buildup in the heart). It may help researchers understand better treatment for symptoms and heart function in this group.
TaipeiAges 60 years+ - NCT04636684Recruiting
Study ATTR deposits in the aortic valve
This study looks at how common ATTR-related protein deposits are in the heart valve of people with age-related (degenerative) aortic stenosis. It may help doctors understand how important these deposits are and could guide future treatment decisions.
ToulouseAges 18–99 - NCT04839003Recruiting
Registry for AL amyloidosis patients to track outcomes
This study collects information from adults with systemic AL amyloidosis to better understand the disease and outcomes. Because it includes pre-treatment records and follows people over time, it may help future patients by improving knowledge of how AL amyloidosis progresses and responds to care.
PaviaAges 18–99 - NCT07110844RecruitingPhase 2
Teclistamab with Daratumumab for Newly Diagnosed AL Amyloidosis
This trial tests a combination of two drugs (teclistamab and daratumumab) for people with AL amyloidosis who have not had prior treatment. The goal is to see if this combination can safely and effectively reduce the abnormal protein deposits in organs.
Boston, MassachusettsAges 18–100 - NCT05101304Recruiting
European registry for people with amyloidosis
This study collects health information from people who may have amyloidosis or who already have a confirmed diagnosis. It aims to better understand amyloidosis in real-world care across European centers, which can help future patients and treatments.
CréteilAges Any age - NCT05444920Recruiting
Web network for people with amyloidosis in Italy
This trial builds an Italian online network to learn from people who may have amyloidosis (an abnormal protein condition). It collects information from participating centers and could help doctors better understand different types of amyloidosis.
Legnano, MIAges 18–99 - NCT05577819Recruiting
Screening for ATTR heart amyloid in older HFpEF patients
This study looks at how often a specific heart condition (ATTR amyloid) occurs in people age 65+ who have HFpEF. It also tries to predict who might have it, using a special heart scan, and may help your care team identify it earlier.
Boston, MassachusettsAges 65 years+ - NCT05652335RecruitingPhase 1
JNJ-79635322 for hard-to-treat myeloma or amyloidosis
This Phase 1 study tests how safe and how well JNJ-79635322 works in people with multiple myeloma that has come back or is resistant to treatment, or AL amyloidosis that has already been treated. It may help by targeting cancer cells and abnormal proteins driving these diseases.
Duarte, CaliforniaAges 18 years+ - NCT05760287Recruiting
Study of heart ultrasound findings in cardiac amyloidosis
This study looks at how cardiac amyloidosis shows up on heart imaging, especially ultrasound (echocardiography). It may help doctors better describe and track the condition using your exam and test results.
Roma, RMAges 18 years+ - NCT05797857Recruiting
Exercise program for transthyretin heart amyloidosis
This trial studies whether a structured exercise training program is safe and helpful for people with transthyretin (ATTR) cardiac amyloidosis. It may help improve fitness and daily functioning, and it may also compare groups for specific eligibility needs.
Boston, MassachusettsAges 60–90 - NCT05898646RecruitingPhase 2
Daratumumab maintenance for AL amyloidosis after initial treatment
This Phase 2 trial studies whether giving daratumumab as ongoing maintenance therapy after your initial AL amyloidosis treatment can improve survival. It may help by keeping the disease under control longer after you have responded to induction therapy.
Scottsdale, ArizonaAges 18 years+ - NCT05929209Recruiting
Studying blood markers in inherited heart-and-nerve amyloidosis
This study looks for “biomarkers” (measurable signs in blood or other tests) to understand inherited transthyretin amyloidosis, including in people who have not yet developed symptoms. Results may help researchers track the condition earlier and better understand how it changes over time.
Roma, IDAges 18 years+ - NCT05950867Recruiting
Testing how common wild-type TTR heart amyloidosis is
This study looks at how often a specific type of heart condition (wild-type TTR cardiac amyloidosis) occurs in people whose nerve symptoms have no clear cause. The results may help doctors spot this treatable problem earlier when neuropathy is unexplained.
Jette, Belgium Capital CityAges 60 years+ - NCT05978661RecruitingPhase 1
FKC288 cell therapy for AL amyloidosis
This trial tests a new cell therapy called FKC288 for people with AL amyloidosis that hasn't been helped by standard treatments. The goal is to see if it can safely control the disease and improve organ function.
Nanjing, JiangsuAges 18–70 - NCT06022939RecruitingPhase 3
Comparing chemo plus stem cell transplant to chemo alone for AL amyloidosis
This study tests whether adding a stem cell transplant to standard chemotherapy (Dara-VCD) works better than chemotherapy alone for people newly diagnosed with AL amyloidosis. It aims to find the best way to control the disease and improve outcomes.
Goodyear, ArizonaAges 18 years+ - NCT06128629RecruitingPhase 3
A study of NTLA-2001 for transthyretin amyloidosis with heart problems
This study tests a new treatment, NTLA-2001, for people with a type of heart disease called transthyretin amyloidosis with cardiomyopathy. It aims to see if the medicine can help improve heart function and quality of life.
Tucson, ArizonaAges 18–90
Hear when a new Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for amyloidosis?
- Yes. Clin2 currently lists 155 recruiting amyloidosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a amyloidosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a amyloidosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.